Inotek Pharmaceuticals Corporation

Rudolf A Baumgartner

William K McVicar

Norman N Kim

Shikha P Barman

Thomas Mccauley

The present invention is directed to a composition or a kit comprising a combination of a prostaglandin analog and an adenosine receptor Aagonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. In some embodiments, the adenosine receptor Aagonist is Compound A, ((2R,3S,4R,5R)-5-(6 -(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate, having the structure, 

Combination, kit and method of reducing intraocular pressure

The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor Aagonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. In one embodiment, the prostaglandin analog is latanoprost and the adenosine receptor Aagonist is Compound A, ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate, having the structure, 

Provided herein are compounds, compositions, and methods for reducing intraocular pressure. Also provided herein are compounds, compositions and methods for the treatment of glaucoma or ocular hypertension.

Growing community of inventors

Sudbury, MA, United States of America

Rudolf A Baumgartner